News items related to: News
-
COVID-19: Another of Gilead’s FIVE patent applications on remdesivir is opposed in Argentina
Our campaign partner, Fundación GEP, has filed a second patent opposition against one of Gilead’s numerous patent applications for the...
-
AIDS 2020 exhibition: Love, life and riots
We’re exhibiting at #AIDS2020Virtual, the world’s largest virtual AIDS conference. Our photo exhibition Love, Life and Riots will be on...
-
What’s on: AIDS 2020 Virtual for treatment activists
Kicking off on Monday 6 July, with a workshop on innovative strategies to reduce prohibitive drug prices, we’ve compiled some...
-
Ukraine: 100% LIFE opposes patent on TB drug for children
Our campaign partner in Ukraine, 100% LIFE, has submitted the first patent opposition on bedaquiline in the Eastern Europe and Central...
-
Argentina: Fundación GEP opposes Gilead’s patent application on remdesivir
Our partner, Fundación GEP, has filed a patent opposition against Gilead’s patent application on remdesivir before the Argentinean Patent Office....
-
COVID-19: Local manufacturing essential if we are to “treat all”
ITPC led a virtual roundtable last week (26 May 2020) attended by civil society treatment experts, researchers, and national pharmaceutical...
-
Moroccan civil society calls for compulsory licence on Gilead’s possible COVID-19 drug
On 12 May 2020, Gilead Sciences announced voluntary licenses to five generic manufacturers in India and Pakistan allowing them to...
-
Brazil and Thailand: Activists oppose more TB patents during COVID-19 pandemic
Bedaquiline (BDQ) is a core component of an ‘all-oral’ solution to multi-drug resistant TB (MDR-TB), and is recommended by the...
-
Civil society asks WHO and Unitaid to ensure equitable access to COVID-19 technologies – and that commitment is binding
In an open letter, sent to Unitaid, the World Health Organization (WHO) and its Member States today, 86 civil society...
-
Activists urge Eurasian states to order more affordable medicines, after HIV patent is dropped
AbbVie has waived its patent rights for HIV drug, lopinavir/ritonavir (LPV/r), in many parts of the world, including for the...
-
COVID-19 pandemic: ‘An opportunity of a lifetime’?
The race is on to find an effective treatment and vaccine for COVID-19. Everyone hopes a solution will be...
-
Global headlines: Potential COVID-19 drugs are over-priced
From the front page of Le Monde, to the Financial Times, Bloomberg, Al Jazeera and others, research demonstrating that potential...